1. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor

   • Nenad Sarapa
   • Margaret R. Britto
   • Kourosh Parivar

   Clinical Trials 11 May 2005 Pages: 247 - 256

   

2. The effects of tramadol on static and dynamic pupillometry in healthy subjects—the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status

   • Frank Fliegert
   • Burkhard Kurth
   • Karin Göhler

   Pharmacodynamics 20 May 2005 Pages: 257 - 266

   

3. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers

   • G. Peytavin
   • C. Gautran
   • R. Farinotti

   Pharmacokinetics and Disposition 12 May 2005 Pages: 267 - 273

4. Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects

   • Kyoung-Ah Kim
   • Sae Ock Oh
   • Ji-Young Park

   Pharmacokinetics and Disposition 25 May 2005 Pages: 275 - 280

   

5. Hyponatremia in elderly patients treated with desmopressin for nocturia: a review of a case series

   • Torbjörn Callréus
   • Elisabet Ekman
   • Morten Andersen

   Pharmacoepidemiology and Prescription 04 May 2005 Pages: 281 - 284

6. Press coverage and sales of Xenical in Sweden, 1998–2000

   • Fredrik Brounéus
   • Anna Dahlin
   • Björn Beermann

   Pharmacoepidemiology and Prescription 14 May 2005 Pages: 285 - 289

   

7. The impact of hospitalisation on the initiation and long-term use of benzodiazepines

   • Rutger Stuffken
   • Rolf P. van Hulten
   • Antoine C. G. Egberts

   Pharmacoepidemiology and Prescription 14 May 2005 Pages: 291 - 295

   

8. Drug utilisation by children and adolescents with mental retardation: a population study

   • H. Tobi
   • T. Scheers
   • R. B. Minderaa

   Pharmacoepidemiology and Prescription 20 May 2005 Pages: 297 - 302

9. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation

   • E. C. G. van Geffen
   • J. G. Hugtenburg
   • A. C. G. Egberts

   Pharmacoepidemiology and Prescription 20 May 2005 Pages: 303 - 307

10. “Medicamentation” of society, non-diseases and non-medications: a point of view from social pharmacology

    • T. B. Ngoundo Mbongue
    • A. Sommet
    • J. L. Montastruc

    Short Communication 14 May 2005 Pages: 309 - 313

11. Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity

    • Craig R. Lee
    • Roy L. Hawke
    • John A. Pieper

    Letter to the Editors 04 May 2005 Pages: 315 - 316

    

12. Relationship between calcineurin inhibition and plasma endothelin concentrations in cyclosporine-A-treated kidney transplant patients—a comment

    • W. Zehngawa

    Letter to the Editors 13 May 2005 Pages: 317 - 317

13. The questionable use of antihypertensive drugs in the Italian Liguria Region in the year 2003

    • Luigi Robbiano
    • Antonietta Martelli
    • Giovanni Brambilla

    Letter to the Editors 13 May 2005 Pages: 319 - 320

14. Controlled withdrawal of selective serotonin reuptake inhibitors in elderly patients in nursing homes with no indication of depression—a commentary

    • Juan Merlo
    • Bo Gullberg

    Letter to the Editors 26 May 2005 Pages: 321 - 323

15. Reply

    • Christer von Bahr

    Letter to the Editors 01 June 2005 Pages: 325 - 326